SG Americas Securities LLC Sells 958 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

SG Americas Securities LLC decreased its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 3.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,011 shares of the technology company’s stock after selling 958 shares during the quarter. SG Americas Securities LLC’s holdings in Simulations Plus were worth $698,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. First Horizon Advisors Inc. raised its stake in shares of Simulations Plus by 82.6% in the third quarter. First Horizon Advisors Inc. now owns 818 shares of the technology company’s stock worth $26,000 after purchasing an additional 370 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Simulations Plus by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock worth $311,000 after buying an additional 456 shares in the last quarter. Pitcairn Co. raised its position in Simulations Plus by 9.1% in the 3rd quarter. Pitcairn Co. now owns 6,599 shares of the technology company’s stock valued at $211,000 after buying an additional 549 shares during the last quarter. Franklin Resources Inc. lifted its stake in Simulations Plus by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 10,797 shares of the technology company’s stock valued at $342,000 after acquiring an additional 766 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in Simulations Plus by 1.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 54,813 shares of the technology company’s stock worth $2,665,000 after acquiring an additional 784 shares during the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Stephens initiated coverage on shares of Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price for the company. KeyCorp increased their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. BTIG Research reduced their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Finally, William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Simulations Plus presently has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. This represents a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 19.40% of the stock is currently owned by insiders.

Simulations Plus Stock Up 1.4 %

SLP opened at $34.27 on Friday. Simulations Plus, Inc. has a twelve month low of $24.00 and a twelve month high of $51.22. The company’s 50-day moving average price is $30.31 and its two-hundred day moving average price is $32.70. The stock has a market cap of $688.48 million, a price-to-earnings ratio of 85.68 and a beta of 0.80.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.